The Latest Cardiac and Vascular News
A Pivotal Step in Optimizing the ADAPT 2.0 Technique for Speed and Simplicity with a Single System Setup ADAPT 2.0 with the Zoom Stroke System CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced the commercial launch and first patient cases of the new Zoom 4S Catheter – an advanced aspiration thrombectomy […]
Paris, France, January 26, 2026 – HighLife SAS, a leading MedTech company focused on transcatheter solutions for structural heart disease, today announced that it has received CE Mark approval for the HighLife Transcatheter Mitral Valve Replacement (TMVR) System for the treatment of adult patients suffering from symptomatic moderate-severe or severe mitral valve regurgitation (MR), […]
IRVINE, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the appointment of John Molyneux to Vice President of Operations, overseeing global manufacturing, engineering, and supply chain operations.
Large-scale NHS trial led by Imperial College London across 200+ NHS practices shows significant gains in early cardiac disease detection through AI-assisted stethoscope exams SAN FRANCISCO, Jan. 29, 2026 /PRNewswire/ — Eko Health, a leader in AI-powered cardiac and pulmonary disease…
COPENHAGEN, Denmark, Jan. 29, 2026 /PRNewswire/ — CathVision today announced significant clinical and scientific progress in Pulsed Field Ablation (PFA) with its PFAnalyzer™ software module, reinforcing the company’s differentiated position in electrophysiology (EP) recording and…
Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that Cibolo Rural Health Networks (“Cibolo Health”) has selected MyoVista Insights™ as its endorsed ECG management platform for independent hospitals within its high-value networks.
ACES-EMB is the first randomized-controlled trial to compare dd-cfDNA surveillance to routine biopsy in organ transplantation, highlighting the benefits of Prospera™ in organ rejection AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial […]
RALEIGH, N.C. and PANAMA CITY, Fla., Jan. 28, 2026 /PRNewswire/ — Compass Surgical Partners (Compass), a leading, independent, full-service ambulatory surgery center (ASC) development and management partner, today announced that it has partnered with local physicians to develop and…
Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial BEDFORD, Mass., Jan. 28, 2026 /PRNewswire/ — Instylla, Inc., a privately held company developing novel…
MADRID, Jan. 28, 2026 /PRNewswire/ — The ReDS-SAFE HF II Trial, a large multicenter investigator-initiated randomized controlled study, funded by both the Instituto de Salud Carlos III and the Spanish Society of Cardiology, has officially commenced. The trial is designed to further…
